Mechanisms of GBA1 related PD in hiPSC derived neurons

DSpace Repository


Dateien:

URI: http://hdl.handle.net/10900/84256
http://nbn-resolving.de/urn:nbn:de:bsz:21-dspace-842560
http://dx.doi.org/10.15496/publikation-25646
Dokumentart: Dissertation
Date: 2018-09-19
Language: English
Faculty: 4 Medizinische Fakultät
Department: Medizin
Advisor: Gasser, Thomas (Prof. Dr.)
Day of Oral Examination: 2018-07-18
DDC Classifikation: 500 - Natural sciences and mathematics
570 - Life sciences; biology
610 - Medicine and health
Keywords: Stammzelle , Nervenzelle , Parkinson-Krankheit
Other Keywords:
ipsc
stem cells
neurodegeneration
GBA1
License: Publishing license including print on demand
Order a printed copy: Print-on-Demand
Show full item record

Abstract:

Parkinson's Disease (PD) is the second most common neurodegenerative disorder after Alzheimers Disease affecting approximately 5% of the population over 80 years of age. The exact mechanisms underlying the disease are not known but environmental as well as genetic factors have been described to contribute to the disease progression. Mutations in the gene GBA1 which encodes for the protein Glucoerebrosidase 1 (GCase) represent the most common genetic risk factor to develop PD and lead to reduced activity of the enzyme GCase. Importantly, considering the clinical representation, GBA1 related PD is similar to sporadic forms of the disease, making underlying mechanisms an interesting target to develop treatment strategies for PD. In the current work we investigate such underlying mechanisms using induced pluripotent stem cell (iPSC) derived neurons from PD patients with GBA1 mutations. We find that such neurons resemble PD associated features like loss of GCase activity, accumulation of alpha synuclein,disturbances in autophagy and calcium homeostasis as well as mitochondrial dysfunction. Finally, we show that application of the Nicotinamid adenosine dinucleotide (NAD) precursor Nicotinamid riboside (NR) partly rescues such defects in iPSC derived neurons as well as in vivo models of PD, making the NAD metabolism a promising target for the treatment of PD.

This item appears in the following Collection(s)